Related Experiment Video

Updated: Sep 30, 2026

Calculating Heart Rate Variability from ECG Data from Youth with Cerebral Palsy During Active Video Game Sessions
08:12

Calculating Heart Rate Variability from ECG Data from Youth with Cerebral Palsy During Active Video Game Sessions

Published on: June 5, 2019

HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction

Sam Riahi1, Jeppe Hagstrup Christensen, Egon Toft

  • 1Department of Cardiology, Aalborg Hospital, Hobrovej, 9000 Aalborg, Denmark. samriahi@dadlnet.dk

Pharmacological Research
|August 7, 2002
PubMed

Insights

Statins may improve heart rate variability (HRV) in patients with a history of myocardial infarction (MI). This finding could help explain the early benefits of statin therapy for coronary heart disease (CHD).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins are known to decrease mortality in patients with coronary heart disease (CHD).
  • The precise mechanisms behind the early beneficial effects of statins are not fully understood.
  • Heart rate variability (HRV) is a marker of autonomic nervous system function and a predictor of cardiovascular outcomes.

Purpose of the Study:

  • To investigate the impact of statin treatment on heart rate variability (HRV) in patients with suspected coronary heart disease (CHD).
  • To explore potential mechanisms for the early beneficial effects of statins in patients with a history of myocardial infarction (MI).

Main Methods:

  • A study included 304 patients undergoing elective coronary angiography for suspected CHD.
  • Twenty-four-hour Holter monitoring was used to assess heart rate variability (HRV).
  • Statistical analyses, including matching for cholesterol levels and multiple linear regression, were performed.

Main Results:

  • Patients with a previous myocardial infarction (MI) who were treated with statins exhibited significantly higher HRV compared to those not on statins.
  • This association remained significant after matching for serum cholesterol and low-density-lipoprotein cholesterol levels.
  • Statin treatment was identified as an independent and significant predictor of increased HRV.

Conclusions:

  • Statin therapy may enhance HRV in patients with a prior MI.
  • The observed increase in HRV could partially account for the early positive clinical outcomes associated with statins in CHD patients.
  • These findings highlight a potential mechanism for statins' cardioprotective effects.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...